Can a Coronavirus Antibody Treatment Knock Out Moderna?
Moderna (NASDAQ: MRNA), the first company to launch a coronavirus vaccine trial in humans, has been the subject of lots of buzz over the past several months. And when people weren't talking about Moderna's progress, they've been talking about its rivals in the race to bring a vaccine to market -- until recently.
After his COVID-19 diagnosis, President Donald Trump took, among other treatments, Regeneron's (NASDAQ: REGN) investigational antibody cocktail. He praised the product and said he would help deliver it to Americans as soon as possible. Soon afterward, the government offered another antibody-cocktail maker -- AstraZeneca (NYSE: AZN) -- $486 million to support its program.
Now the question is: Can these investigational antibodies for COVID-19 treatment and prevention push vaccine makers out of the limelight? Let's take a closer look.
Source Fool.com
